public-private partnerships in life sciences co-creation ... · co-creation funding for whom? for...

Public-Private Partnerships in Life Sciences – Co-creation, Co-innovation and

how to get Started?

27.9.2019Outi Tuovila

Agenda

9.00 Opening

Outi Tuovila, Senior Advisor, Business Finland

9.05 Business Finland research funding

Pekka Ollikainen, Senior Advisor, Business Finland

9.20 Co-innovation case: New modalities

Antti Haapalinna, Vice President, R&D, Rare Diseases, Biologics and New Modalities, Orion Oyj

9.35 Co-innovation case: ADELE

Aki Sinkkonen, PhD, PI, Adjunct Professor, Faculty of Biological and Environmental Sciences, University of Helsinki

9.50 Q&A

10.00 Presentation of co-creation projects

moderator: Hanna Rantala, Director, Business Finland

11.00 Networking and lunch

12.00 The event ends

BUSINESS FINLAND

Co-CREATION FUNDING

Research organizations

27.9.2019 Pekka Ollikainen

Co-Creation Develop a research idea, build on

cooperation

Research organizations and companies develop the research idea.

The funding will ensure the demand and suitability of a new research goal (problem to be solved) to businesses and construction of a new co-operation.

New business from research ideas (TUTLI)

Create new knowledge and business applications from research ideas

Business Finland –tutkimusrahoi

Research organisations develop new knowledge and solution models for new business purposes and and companies develop innovations for the global market.

Funding advances the use of research knowledge, increases the creation of new Finnish export products and strengthens networks in ecosystems.

Co-InnovationSearch for solutions with the help of research, cooperate and develop new export products

International and other special calls (ESA, ERDF, Eureka etc.) have their own specific criteria

Our funding services for research

Research organisations prepare an idea for business purposes.

Funding advances the commercialisation of research ideas.

4

Two paths to funding

If you have a new idea that could open up significant business opportunities for companies and you want to• Investigate and develop the idea

and its potential together with companies

• Create a consortium required for work and engage companies in development work

First contact the Research Funding Team of Business Finland for feedback on the idea. You may want to apply for Co-Creation funding.

If you already have the necessary companies committed to the project and development work already in the consortium, and you will be able to demonstrate the problem associated with the issue and the impact of its solution to the emergence of a significant business.

First contact the Research Funding Team of Business Finland for feedback and sparring. You may want to apply for Co-Innovation funding. 5

1 2

Co-Creation fundingFor whom?

For research organisationsaiming at to a Co-Innovation project to be completed in close co-operation with companies

For what purpose?

Research organisations and companies jointly develop a research idea. The goal is to create a Co-Innovation project (joint action) among companies and researchers.

Funding ensures the need for the research goal and the solution and its suitability for business use. It also helps build a network for a possible Co-Innovation project.

Not necessary for all: Formed consortiums can advance directly to the Co-Innovation funding phase.

6

Co-Creation funding

How does it work?

Funding covers 60% of the project’s total expenses

The maximum size of the project is 100 000 euros.

Project duration 4–6 months

Fixed overhead percentage 20% and coefficient for indirect employee costs 50%

Equipment costs are not accepted

No application period

Final report, no audit7

Applying for Co-Creation fundingContact the Research Funding Team of Business Finland and prepare in advance to tell your idea:

NEED

What is the problem solved by the research idea?Has the matter been discussed with companies (which companies)? Are companies willing to participate in development work?Is Co-Innovation Consortium required to stage the company already ready?

BENEFIT

If your research succeeds, what kind of business opportunities will be created?What is the preliminary estimate based on?What kind of businesses could interest the subject?

SOLUTION

How is the solution sought (solution model)?

COMPETITION

Has the subject been studied elsewhere, and where? What's new here? Has this been previously funded

8

Co-Creation funding

What are the criteria for the funding?

The novelty value and business potential of the idea

The quality of the plan to determine the relevance of the idea and demand (problem-solution fit)

The quality of the plan to create cooperation with companies and the R&D consortium

Including Business Finland’s strategic and programmes´ themes in the plan will positively influence the evaluation process. 9

What kind of work is funded in Co-Creation project?

The demonstration the relevance of the research idea and the relevant demand for the subject, to further develop and improve the idea

The creation of an interaction model and a business network as well as an international network needed in research and innovation development (freedom of action in the area, IPR, ...)

Other matters related to the feasibility of the idea of work

The application defines the preliminary problem to be solved and its solution model. This idea must be widely utilized.

The project deepens understanding of the importance of the problem and the solution model and whether it is solving the right problem.

10

Contact our Research Funding Team!

11

Mika Lautanala

+358 50 557 7838

Digitalisation

Kimmo Ahola

+358 50 557 7756

Consumer Business

Kenneth Nyholm+358 50 395 6028

Bio and CircularEconomySisko Sipilä

+358 50 557 7845

Cleantech

Kari Koskela

+358 50 439 5736

Health and Wellbeing

Pekka Ollikainen

+358 50 557 7758

Emails:

[email protected]

9-2019-vpo

You may also contact to your named contact person at Business Finland

Co-innovation case: New modalities

Antti Haapalinna, Professor, Ph.D, eMBA

Vice President, R&D

Global Head, Therapy Area Rare Diseases,

Biologics, Biomarkers and New Modalities

Function

Orion Corporation, ORION PHARMA

Public-Private Partnerships in Life Sciences – Co-creation,

Co-innovation and how to get Started?

Helsinki 27.9.2019

World has become and is becoming more complex ...

Regulatory

• Price regulations increasing

• Reimbursement requirements increasing

• Scrutiny on drug efficacy and safety intensifying

• Time span of regulatory processes extending

Technology

• R&D productivity more challenging

• Role of biologicals has increased

• Alternative technologies emerging

• Industry consolidation intensifying

• Digitalization /E-commerce opportunities

broadening

Consumer

• Population aging

• Health awareness intensifying

• Demand for personalised therapy increasing

• Service concepts broadening

• New distribution channels emerging

• Private spend on medicines increasing

Open

Science

RECENT

THEMES

Disruptive

innovations

Social

media

Big data Companion

diagnostics

Open

innovation

Biobanks

Advanced

therapies

Customer/

patients on

focus

Socio-economic

• Economic downturn still influencing

• Role of innovations as growth driver increasing

• Number of generic launches increasing

• Growth in emerging markets increasing

• Competition intensifying

• Numerous market specific payer actions

emerging

© Orion R&D

Why ? What ? How?

Operational environment is dramatically changing. New technologies are emerging,

attrition is high because lack of efficacy, price and reimbursement regulations increasing,

large diseases will be fragmented, patient stratification important. More and more target

proteins emerging that are not amenable for small molecules. Need for real world data

for clinical benefit.

We need to build competencies for new treatment modalities in addition to small

molecules. Rare monogenic diseases provide a way for less risky, systematic target

(protein or gene) selection for application of new technologies. As well as reveal

biochemical pathways that possibly results in treatment of a more common condition.

Start to broaden our competencies for biologics (therapeutic proteins) with systematic

piloting of other new technologies. Start with Finnish genetic Rare diseases, providing

excellent genetic and clinical basic research and network.

Antti Haapalinna Orion Oyj

More and more target proteins emerging that are not amenable for small

molecules. When having competencies in biologics, there is an opportunity to

combine mAbs with small molecule competencies regarding antibody drug conjugates (ADC)

ADC (antibody drug conjugate)

Darolutamide

C19H19ClN6O2

399 g/mol

IgG2a Antibody

C6440H9962N1704O2014S56

146,277 g/mol

Monoclonal

Antibody

(mAb)

Antti Haapalinna Orion Pharma

• Small molecules

• Biologics (mAb, affinity proteins)

• Therapeutic peptides

• Therapeutic nucleic acids

• Gene therapy…

● There are between 6000 and 8000 rare diseases.

30 million individuals each in EU and USA have

Rare (orphan) diseases

● 75 % of rare diseases affect children

● 80 % of rare diseases have identified genetic

origin which means that reason for condition

is known.

● Many rare diseases remain without effective

treatments

● The genetic origin is identified for all

of the 36 rare diseases

● In many of these diseases a single point

mutation leads to a single amino acid

substitution and a defective protein

Finnish Disease HeritageRare Diseases

Rare genetic diseases may provide a way for less

risky systematic target selection for application of

new technologies than common disease where

ultimate reason of the disease is not known

16

Genetic

defect

Dysfunctional

proteinDisease and

symptoms

Pathological

process

• Disease Biology understanding

• Patient stratification

• Meaningful clinical end points

• New technology /real world

Data / evidence

17

From one ecosystem to multiple parallel ecosystems

Business Finland grant,

positive decision obtained

at 28th August 2018 for

New Modalities

Ecosystem for developing

capabilities in Rare

Diseases, Biologics and

New Treatment Modalities https://www.businessfinland.fi/en/w

hats-new/news/2018/creation-of-

novel-medicines-and-better-

patient-care-for-the-future-in-an-

ecosystem/


https://www.businessfinland.fi/en/whats-new/news/2018/creation-of-novel-medicines-and-better-patient-care-for-the-future-in-an-ecosystem/

● 20 March 2018 First visit to Business Finland

– BF: ”Would Orion build an ecosystem” ?

● 21st March – 28 April; first contacts, meetings and writing plans with the ecosystem partners

● 30 April 2018 all applications filed at the same time with Orion

● 28 August BF BOD approval for the Ecosystem

– Starting of actual work

● Ecosystem contract ready and signed in spring 2019

“Where there's a will there's a way”

“The aim of this New Modalities Ecosystem is enable improved understanding of disease pathology related to

the symptoms and disease progression and better treatments by applying large molecular drugs and diagnostic

tools as well as digital wearable patient tools for disease symptom recording. This Ecosystem combines in a

unique way high-level academic research with industrial drug research and development. The Ecosystem

participants include in addition to Orion, University of Turku, University of Helsinki, University of Eastern

Finland, Folkhälsan as well as the companies PerkinElmer, Syrinx Bioanalytics, AdmeScope, Petsofi, Forendo

Pharma.”


Knowledge and technology ecosystem

A bridge between technology and biology


Disease Biology

understanding New treatments

technologies

understanding

Building an ecosystem for developing capabilities in

Rare Diseases, Biologics and New Treatment Modalities

Syrinx Bioanalytics

Biomarkers

Admescope

Bioanalytics

DMPK

Ecosystem for developing capabilities in

Rare Diseases

• Increased knowledge on disease-specific

as well as common biochemical pathways

• Novel drug targets

• Diagnostic tools and biomarkers for

patient stratifications and clinical trials

• Wearable patient tools; sensors for

myoclonus detection and for patient on-

line reporting of their condition

Disease Biology understanding, patient stratification,

Meaningful clinical end points, real world evidenceBiomolecule and technology knowledge and tools


Progressive Myoclonus

Epilepsy, EPM1

Common features• Juvenile onset of disease

• Neurodegeneration with same brain areas

• Similar kind symptoms; severe disabilities

in motor coordination

21

Understanding and

measurement of symptoms

• Meaningful clinical end

points

• New technology /real

world Data / evidence

Common and specific target proteins in

movement disorder syndromes

and biochemical pathways possibly resulting

in treatments also of more common

conditions (e.g. Parkinson’s disease)

Mitochondrial Recessive

Ataxia Syndrome, MIRAS

Anu Wartiovaara MD, PhD,

Academy ProfessorReetta Kälviäinen MD, PhD,

Professor of Neurology

Anna-Elina Lehesjoki

MD, PhD, Professor of

Medical Genetics

Disease Biology

understanding and

measurement

• Diagnostic tools and

biomarkers for patient

selection and

following efficacy in

clinical trials


Target confidence, patient stratification

Meaningful clinical end pointsMolecule and technology confidence

A bridge between technology and biology



Modality agnostic approach

select the most appropriate

drug targets to provide best

treatment for patients without

limitations to certain treatment

modalities

Building knowledge ecosystem to

provide

Biologics (mAb, affinity

proteins)

Therapeutic peptides

Therapeutic nucleic acids

Targeted Delivery of Oligonucleotide-based Drugs

Bioorganic group, Professor Pasi Virta/

Urpo Lamminmäki /Recombinant Protein Platforms for Drug Lead Discovery by the antibody

engineering group

Companies for technology ecosystem:

Technology ecosystem


SYRINX Bioanalytics

● Pharmacokinetic assays for next generation oligonucleotides and targeted delivery

● New analytical challenges for immunogenicity testing

● Pharmacodynamic biomarker assays related to the use of oligonucleotide therapies

Admescope

● Analytical methodology for therapeutic nucleotides and peptides for distribution, pharmacokinetics, metabolomic faith, cell entrance and

biological effects and efficiency

● Ligand binding methods for immunochemical and biological properties of New modalities

● Drug-drug-interactions of New modalities

Forendo Pharma

● core competence in tissue-specific regulation of sex hormone effects.


Disease Biology understanding, patient stratification

Meaningful clinical end points, new technology /real world

data/ evidence

Biomolecule and technology confidence

A bridge between technology and biology • Increased knowledge on disease-specific as well

as common biochemical pathways

• Diagnostic tools and biomarkers for patient

stratifications and clinical trials

• Wearable patient tools; sensors for myoclonus

detection and for patient on-line reporting of their

condition Modality agnostic approach

select the most appropriate drug targets to provide best

treatment for patients without limitations to certain

treatment modalities

Building knowledge and technology ecosystem to provide

Biologics (mAb, affinity proteins)

Therapeutic peptides

Therapeutic nucleic acids


Business Finland

public private funding

(for 3 years) received

28.8.2018

Ecosystem agreement

• Common frame for collaboration

• To protect background data

• Enabling publishing and data protection

Agreements between parties for IPR sensitive issues

Joint yearly event for all participants at Orion training

center in mid June.


26

It is important to industry to

understand clinical practice

New medicines to

patients / clinical trials

Offering academia opportunities e.g. access to new

molecules => expand knowledge of MoA / disease

mechanisms

Basic research findings

New technologies

Medical

knowledge of

TA & MoA

Samples:

Disease -

Biomarker

discovery

Adverse effect

monitoring

New treatments

Devices

Diagnostics

Enabler & coordinator

Help to identify key priorities

Provide project management enablers

Regulatory knowledge

ACADEMIA COMPANIES(large and SMEs)

HEALTHCARE

PROFESSIONALS

Samples

Mutual desire: Provide patients with access to new

more effective and safe treatments and care (from Open Science to Open innovation)

© Orion R&D

Press releases:

https://www.businessfinland.fi/ajankohtaista/uutiset/2018/tulevaisuuden-laake--ja-hoitomuotoja-kehitetaan-ekosysteemissa/

https://www.orion.fi/konserni/media/lehdistotiedotteet/2018/tulevaisuuden-laake--ja-hoitomuotoja-ekosysteemissa/

https://www.orion.fi/en/Orion-group/media/press-releases/2018/creation-of-novel-medicines-and-better-patient-care-for-the-future-in-an-ecosystem/

http://www.globenewswire.com/news-release/2018/09/17/1571506/0/en/Creation-of-novel-medicines-and-better-patient-care-for-the-future-in-an-ecosystem.html

https://www.helsinki.fi/fi/uutiset/terveys/helsingin-yliopisto-ja-orion-oyj-yhdistavat-voimansa-mitokondriotautien-ja-etenevan-myoklonusepilepsian-hoitotutkimuksessa

https://www.utu.fi/fi/Ajankohtaista/mediatiedotteet/Sivut/Turun-yliopisto-kehittaa-tulevaisuuden-laake-ja-hoitomuotoja-osana-laajempaa-ekosysteemia.aspx

Articles:

http://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pnum=156&edid=73e202a8-1e25-4d2e-afc3-1cd95c26e5ae&isshared=true

http://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pnum=158&edid=5ffe2a2a-df10-462e-a709-5910f039b796&isshared=true

Collaboration on education:

https://www.utu.fi/fi/ajankohtaista/uutinen/turun-yliopisto-ja-orion-oyj-ryhtyvat-kouluttamaan-yhteistyossa

Q&A?


https://www.businessfinland.fi/ajankohtaista/uutiset/2018/tulevaisuuden-laake--ja-hoitomuotoja-kehitetaan-ekosysteemissa/

https://www.orion.fi/konserni/media/lehdistotiedotteet/2018/tulevaisuuden-laake--ja-hoitomuotoja-ekosysteemissa/

https://www.orion.fi/en/Orion-group/media/press-releases/2018/creation-of-novel-medicines-and-better-patient-care-for-the-future-in-an-ecosystem/

http://www.globenewswire.com/news-release/2018/09/17/1571506/0/en/Creation-of-novel-medicines-and-better-patient-care-for-the-future-in-an-ecosystem.html

https://www.helsinki.fi/fi/uutiset/terveys/helsingin-yliopisto-ja-orion-oyj-yhdistavat-voimansa-mitokondriotautien-ja-etenevan-myoklonusepilepsian-hoitotutkimuksessa

https://www.utu.fi/fi/Ajankohtaista/mediatiedotteet/Sivut/Turun-yliopisto-kehittaa-tulevaisuuden-laake-ja-hoitomuotoja-osana-laajempaa-ekosysteemia.aspx

http://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pnum=156&edid=73e202a8-1e25-4d2e-afc3-1cd95c26e5ae&isshared=true

http://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pnum=158&edid=5ffe2a2a-df10-462e-a709-5910f039b796&isshared=true

https://www.utu.fi/fi/ajankohtaista/uutinen/turun-yliopisto-ja-orion-oyj-ryhtyvat-kouluttamaan-yhteistyossa

Bio- ja ympäristötieteellinen tiedekunta

Aki Sinkkonen* and the ADELE team* ** ***

*University of Helsinki, Ecology and Environment Research Program **Tampere University of Technology, School of Architecture

***University of Tampere, Faculty of Medicine and Life Sciences

CASE ADELE

18/10/2019Helsinki 2019 28


FROM INFECTIOUS DISEASES TO IMMUNE-MEDIATED DISEASES

18/10/2019Helsinki 2019 29

Identify the problem


IMMUNE-MEDIATED DISEASES

• If harmless environmentalmicrobiota is rare

→ immune system finds alternative targets

- Own cells, e.g. type 1 diabetes

- Gut microbes, e.g. irritable bowel syndrome

- Pollen or food particlesallergies

20 % of people affected in welfare states

18/10/2019 30


SOLUTION

• Diverse nature-derived microbiota

18/10/2019Presentation Name / Firstname Lastname 31


BIODIVERSITY PRODUCTS IN 2020’S

18/10/2019 32Helsinki 2019 – [email protected]


WHO IS INTERESTED IN THIS IDEA?

33

STEP 1:

FIND THE RIGHT PARTNERS IN RESEARCHER COMMUNITY

STEP 2:

FIND THE RIGHT COLLABORATORS FROM ENTERPRISES

TENS (HUNDREDS) OF CALLS

30 VISITS

20 FAILS

WE HAVE A CONSORTIUM

EMAIL = FAIL


REASONS FOR FAIL?

TOO HIGH PRICE TAG

TOO FAR FROM CURRENT RESEARCH AND DEVELOPMENT

TOO EAGER TO JOIN = NO UNDERSTANDING OF RESEARCH

CHANGES IN OWNERSHIP

SUDDEN DROP IN REVENUE



REASONS FOR SUCCESS?

• High quality consortium

• Karolinska Institutet

• Technische Universität Darmstadt

• Opponent (Technische UniversitätGraz) of a Ph. D. defense is nowinvolved




• CLEAR UNDERSTANDING OF BUSINESS OPPORTUNITY

• WE HELPED IN WRITING THE APPLICATION




• KEY PERSONNEL KNOWS THE SCIENCE

• WE PROPOSED HOW TO INTEGRATE US WITH THEIR CURRENT R&D




• RIGHT BACKGROUND OF THE COMPANY

• GOOD ECONOMY

• NOT TOO BIG FAST DECISIONS

• KEY PERSONNEL KNOWS FINNISH UNIVERSITY SYSTEM




• ATTITUDE

• THOSE WHO TAKE R&D RISKS ARE LIKELY TO SAY YES

• DIPP


• Orion oyj

• Delipap oy



• PATENTING

• FIGHT AGAINST DEVIL’S ADVOCATES

• DO IT BEFORE PUBLISHING

• AS TIME CONSUMING AS FINDING PARTNERS


• Orion oyj

• Delipap oy


SHOW UNPUBLIHSED RESULTS

Avoid jargon

20/3/[email protected] 41

0

1

2

3

4

5

6

Interventio Kaupunki Luonto

Ennen Jälkeen

0

2

4

6

8

10

12

14


Ennen Jälkeen

0

1

2

3

4

5


Ennen Jälkeen

Special thanks to Heikki Hyöty’s and Juho Rajaniemi’s groups at Tampere University

[email protected]

www.helsinki.fi/nature-based-solutions

Right clothes and smile

Presentation of co-creation projects

Questions:1. What problem are you trying to solve?2. What is your vision/solution and what you need to achieve it?3. What is the ideal consortium for the purposes of the research (co-innovation project) - what kind of partners you are looking for?

1. Vesa Linnamo, University of Jyväskylä: SilverEconomy

2. Jarmo Perttunen, TAMK: Haavan lämpökuvaus älypuhelimella

3. Arto Pesola / Xamk Active Life Lab: CogTail

4. Tomasz Sokalski, Åbo Akademi University: Intelligent Artificial Nose and Tongue Technology – ANTTI

5. Hanna-Leena Alakomi, VTT: Added value for Finnish food export products, innovative logistics

Outi [email protected]+358 50 339 2542

http://www.businessfinland.fi/personalizedhealth

mailto:[email protected]

public-private partnerships in life sciences co-creation ... · co-creation funding for whom? for...

Documents